ZLB Behring’s Vivaglobin Is First Patient-Administered Immunoglobulin Therapy
This article was originally published in The Pink Sheet Daily
FDA’s approval of the subcutaneous IG replacement therapy provides an alternative to intravenous treatment of primary immune deficiency.
You may also be interested in...
MedImmune divests the transplantation treatment to ZLB Behring for an up-front payment of $50 mil.
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.